493 related articles for article (PubMed ID: 26457758)
21. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.
Dunn LK; Mohammad KS; Fournier PG; McKenna CR; Davis HW; Niewolna M; Peng XH; Chirgwin JM; Guise TA
PLoS One; 2009 Sep; 4(9):e6896. PubMed ID: 19727403
[TBL] [Abstract][Full Text] [Related]
22. In vivo RyR1 reduction in muscle triggers a core-like myopathy.
Pelletier L; Petiot A; Brocard J; Giannesini B; Giovannini D; Sanchez C; Travard L; Chivet M; Beaufils M; Kutchukian C; Bendahan D; Metzger D; Franzini Armstrong C; Romero NB; Rendu J; Jacquemond V; Fauré J; Marty I
Acta Neuropathol Commun; 2020 Nov; 8(1):192. PubMed ID: 33176865
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.
Lu A; Pallero MA; Lei W; Hong H; Yang Y; Suto MJ; Murphy-Ullrich JE
Am J Pathol; 2016 Mar; 186(3):678-90. PubMed ID: 26801735
[TBL] [Abstract][Full Text] [Related]
24. Loss of the calmodulin-dependent inhibition of the RyR1 calcium release channel upon oxidation of methionines in calmodulin.
Boschek CB; Jones TE; Smallwood HS; Squier TC; Bigelow DJ
Biochemistry; 2008 Jan; 47(1):131-42. PubMed ID: 18076146
[TBL] [Abstract][Full Text] [Related]
25. Correlation between extent of osteolytic damage and metastatic burden of human breast cancer metastasis in nude mice: real-time PCR quantitation.
Tester AM; Sharp JA; Dhanesuan N; Waltham M; Thompson EW
Clin Exp Metastasis; 2002; 19(5):377-83. PubMed ID: 12198765
[TBL] [Abstract][Full Text] [Related]
26. Control of muscle ryanodine receptor calcium release channels by proteins in the sarcoplasmic reticulum lumen.
Beard NA; Wei L; Dulhunty AF
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):340-5. PubMed ID: 19278523
[TBL] [Abstract][Full Text] [Related]
27. Nox4 - RyR1 - Nox2: Regulators of micro-domain signaling in skeletal muscle.
Cully TR; Rodney GG
Redox Biol; 2020 Sep; 36():101557. PubMed ID: 32506037
[TBL] [Abstract][Full Text] [Related]
28. PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure.
Reiken S; Lacampagne A; Zhou H; Kherani A; Lehnart SE; Ward C; Huang F; Gaburjakova M; Gaburjakova J; Rosemblit N; Warren MS; He KL; Yi GH; Wang J; Burkhoff D; Vassort G; Marks AR
J Cell Biol; 2003 Mar; 160(6):919-28. PubMed ID: 12629052
[TBL] [Abstract][Full Text] [Related]
29. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.
Hesse E; Schröder S; Brandt D; Pamperin J; Saito H; Taipaleenmäki H
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30965315
[TBL] [Abstract][Full Text] [Related]
30. The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.
Fournier PG; Juárez P; Jiang G; Clines GA; Niewolna M; Kim HS; Walton HW; Peng XH; Liu Y; Mohammad KS; Wells CD; Chirgwin JM; Guise TA
Cancer Cell; 2015 Jun; 27(6):809-21. PubMed ID: 25982816
[TBL] [Abstract][Full Text] [Related]
31. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T
Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006
[TBL] [Abstract][Full Text] [Related]
32. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor-beta in osteolytic breast cancer bone metastases.
Guise TA; Chirgwin JM
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S32-8. PubMed ID: 14600590
[TBL] [Abstract][Full Text] [Related]
34. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.
Kominsky SL; Doucet M; Brady K; Weber KL
J Bone Miner Res; 2007 Jan; 22(1):37-44. PubMed ID: 17032147
[TBL] [Abstract][Full Text] [Related]
35. Local effects of malignancy on bone.
Brown SA; Clines GA; Guise TA
Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):436-41. PubMed ID: 17982348
[TBL] [Abstract][Full Text] [Related]
36. Imperatoxin a enhances Ca(2+) release in developing skeletal muscle containing ryanodine receptor type 3.
Nabhani T; Zhu X; Simeoni I; Sorrentino V; Valdivia HH; García J
Biophys J; 2002 Mar; 82(3):1319-28. PubMed ID: 11867448
[TBL] [Abstract][Full Text] [Related]
37. Reduced Dentin Matrix Protein Expression in Camurati-Engelmann Disease Transgenic Mouse Model.
Gullard A; Croney CM; Wu X; Mamaeva O; Sohn P; Cao X; MacDougall M
J Cell Physiol; 2016 May; 231(5):1106-13. PubMed ID: 26427011
[TBL] [Abstract][Full Text] [Related]
38. Ca(2+) sparks operated by membrane depolarization require isoform 3 ryanodine receptor channels in skeletal muscle.
Pouvreau S; Royer L; Yi J; Brum G; Meissner G; Ríos E; Zhou J
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5235-40. PubMed ID: 17360329
[TBL] [Abstract][Full Text] [Related]
39. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
Miller RE; Jones JC; Tometsko M; Blake ML; Dougall WC
J Thorac Oncol; 2014 Mar; 9(3):345-54. PubMed ID: 24496001
[TBL] [Abstract][Full Text] [Related]
40. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
